BioSpace News Archive

The global organic banana market is expected to post a CAGR close to 11% during the period 2019-2023, according to the latest market research report by Technavio.

UNC School of Medicine researchers identify anorexia nervosa genetic variants, redefine disorder as metabolic and psychiatric

Today’s announcement expands distribution of the branded ingredient to North America and underscores Atacama Bio’s commitment to be a global supplier of natural astaxanthin.

Spectral MD receives $27 million under a 22-month contract, which can be extended for a total of up to $92 million

Diane Parks and Yongxin Han Deepen Expertise in Oncology and Integration of Drug and Delivery Technology

Dassault Systèmes announced the five-year extension of its collaboration with the U.S. Food and Drug Administration.

Samsung Bioepis Co., Ltd. announced that the US Food and Drug Administration has approved HADLIMA™, a biosimilar referencing HUMIRA® i, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA.

The incidence of urethral stricture disease, in which the urethral opening becomes narrow due to genetic disorders, scars, or infections such as STD, is increasing significantly.

Bright Health announced it will begin offering its innovative Health Plan Care Partner Model in 13 new markets across seven states in 2020 plus expanded product offerings in every existing market.